Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.31 |
| ▸ | USP2 | O75604 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27372532 | 1.00 | HSD11B1 (0.34) | HSD11B1CYP2C19ALDH1A1MAPK1MGLL | |
| SCHEMBL31691571 | 0.89 | GRM5 (0.45) | CYP2C19ALDH1A1MAPK1GRM5PDCD1 | |
| SCHEMBL15155193 | 0.88 | HRH3 (0.33) | CYP2C19ALDH1A1MAPK1MGLLSCN9A | |
| SCHEMBL16835525 | 0.87 | GRM5 (0.33) | HSD11B1CYP2C19ALDH1A1MAPK1GRM5 | |
| SCHEMBL9994782 | 0.83 | VNN1 (0.35) | CYP2C19VNN1 | |
| SCHEMBL26633897 | 0.82 | HSD11B1 (0.33) | HSD11B1CYP2C19ALDH1A1MAPK1MGLL | |
| SCHEMBL19972691 | 0.82 | HSD11B1 (0.33) | HSD11B1CYP2C19ALDH1A1MAPK1MGLL | |
| SCHEMBL3723443 | 0.82 | HSD11B1 (0.33) | HSD11B1CYP2C19ALDH1A1MAPK1MGLL | |
| SCHEMBL29418104 | 0.81 | HSD11B1 (0.42) | HSD11B1CYP2C19ALDH1A1MAPK1MGLL | |
| SCHEMBL28466977 | 0.79 | HSD11B1 (0.32) | HSD11B1CYP2C19ALDH1A1MAPK1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4361163-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| US-11319312-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED | 2022-05-03 | — | — | US | disclosed |
| EP-3810607-A1 | OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-10858352-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2019243850-A1 | OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-8889702-B2 | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-11-18 | — | — | US | disclosed |
| EP-2430012-B1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| EP-2393809-B1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
| EP-2393809-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089510-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | HSD11B1 8/4885CYP2C19 78/4885ALDH1A1 176/4885 |
| US-11319312-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | HSD11B1 1512/4885CYP2C19 384/4885ALDH1A1 2679/4885 |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | HSD11B1 726/4885CYP2C19 106/4885ALDH1A1 532/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | HSD11B1 785/4885CYP2C19 1272/4885ALDH1A1 1896/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | HSD11B1 785/4885CYP2C19 1272/4885ALDH1A1 1896/4885 |
| US-10858352-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | HSD11B1 1512/4885CYP2C19 384/4885ALDH1A1 2679/4885 |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | HSD11B1 1512/4885CYP2C19 384/4885ALDH1A1 2679/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | HSD11B1 785/4885CYP2C19 1272/4885ALDH1A1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.